C4 Therapeutics, a preclinical biotech developing small molecule protein degraders to treat cancer, raised $182 million by offering 9.6 million shares at $19, above the range of $16 to $18. The company offered 0.8 million more shares than anticipated. At pricing, the company raised 22% more in proceeds than expected.
C4 Therapeutics plans to list on the Nasdaq under the symbol CCCC. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as joint bookrunners on the deal.
